Indeed, VISTA overexpression in tumor-infiltrating lymphocytes and CD68+ macrophages cells following ipilimumab therapy might be the reason for the low response rate of this monotherapy in patients with prostate cancer (45) (Figure 2). This evidence concerns the gene VSIR and prostate carcinoma.